

BME - GROWTH

Palacio de la Bolsa
Plaza de la Lealtad, 1
28014 Madrid

Alicante, 13th October 2023

COMMUNICATION- OTHER RELEVANT INFORMATION - FACEPHI BIOMETRIA, S.A.

Dear Sirs,

Under the provisions of article 17 of the Regulation (EU) No. 596/2014 on market abuse, and article 227 of the Law 6/2023 17th March, Spanish Securities Market and Investment Services, and related provisions, as well as in the Circular 3/2020 of BME Growth, we inform you about the following information related to the company FACEPHI BIOMETRIA, S.A. (hereinafter "FacePhi" or "the Company", interchangeably).

The Company published last 21st July the resolutions adopted by the Extraordinary General Shareholders' Meeting held on that date, which included, as the first point, the delegation to the Board of Directors of the power to issue notes convertible into shares of the Company in favour of Nice & Green, S.A. ("Nice & Green"), with the exclusion of pre-emptive subscription rights, for a maximum conversion amount of €20,000,000, as well as to increase the share capital by the amount necessary to cover the conversion of said notes.

Last 6th October, the Board of Directors adopted a resolution, under the aforementioned delegation of powers, to issue a second issuance of 190 convertible bonds for a total nominal amount of 1,900,000 euros ("Convertible Bonds OCTOBER 2023"), and Nice & Green is the sole beneficiary of this issuance.

Nice & Green, under the provisions of the investment agreement, notified to the Company and exercised its right to convert 80 Notes (October 2023) for a conversion amount of 800,000 euros.

As a consequence of the above, and after the Company has granted the issuance of the Bonds, the Company will grant a capital increase deed in order to cover the notes' conversion. The new shares of the Company (470,506 shares) are issued with a share premium of €1.6603 per share, the issue price of the shares being €1.7003 per share (€0.04 par value plus €1.6603 share premium).

Following the aforementioned capital increase, the share capital will be € 840,102.80, represented by 21,002,570 numbered from 1 to 21,002,570 shares of € 0.04 nominal value each, of the same class, equal, cumulative and indivisible.

In compliance with Circular 3/2020 of the segment BME Growth of BME MTF Equity, it is expressly stated that the information hereby communicated has been produced under the sole responsibility of the company and its administrators.

We remain at your disposal for any clarification you might deem necessary.

Sincerely,

Javier Mira Miró

Chairman of the Board of Directors